

SOHEIL SIMZAR, MD

Double board-certified dermatologist and Mohs micrographic surgeon

Soheil.Simzar@gmail.com

EXPERT WITNESS PROFILE

Full-spectrum dermatology expert with extensive clinical and procedural experience across medical, surgical, and cosmetic dermatology. High-volume operative background (30,000+ dermatologic surgeries) with a practical understanding of outpatient dermatology workflows, documentation standards, patient counseling, and complication management. Provides independent, well-supported opinions with an emphasis on accepted standards of care, reasonable physician judgment, and the clinical context available at the time of care. Available for record review, deposition, and trial testimony for plaintiff or defense, including defense-oriented standard-of-care analyses when requested.

Scope of Opinions

- **Medical** dermatology: inflammatory, infectious, autoimmune, allergic/contact, pigmentary, hair/nail, and complex rashes/dermatitis
- **Surgical** dermatology: biopsies/excisions, skin cancer management, reconstruction, wound healing, scars, and post-procedural complications
- **Aesthetic** dermatology: neuromodulators (Botox), dermal fillers, lasers/energy-based devices, and management of adverse events
- **Wounds/burns/ulcers**: assessment, treatment planning, healing complications, scarring, and documentation/aftercare standards

Areas of Expertise

- General dermatology; medical dermatology; dermatology standard of care; diagnosis and management of skin conditions
- Rashes/dermatitis; eczema/atopic dermatitis; contact dermatitis; urticaria; psoriasis; seborrheic dermatitis; drug eruptions
- Acne; rosacea; pigmentary disorders (hyperpigmentation, melasma, dyspigmentation)
- Ulcers; chronic wounds; wound care; burns; scars; hypertrophic scars/keloids; scar revision; wound-healing complications
- Hair and nail disorders (alopecia-related evaluations; nail disease)
- Biopsy technique; clinic documentation; informed consent; counseling; follow-up and surveillance; referral/triage
- Mohs micrographic surgery; dermatologic surgery; skin cancer (basal cell carcinoma, squamous cell carcinoma, melanoma) when applicable
- Reconstruction (linear repairs, complex closures, flaps, grafts); post-operative complications
- Cosmetic dermatology: Botox/neuromodulators; dermal fillers; lasers/energy-based devices; complications (burns, dyspigmentation, scarring, vascular compromise)

BOARD CERTIFICATIONS AND PROFESSIONAL AFFILIATIONS

Board Certification: Dermatology, Re-certified August 2018

Board Certification: Mohs Micrographic Surgery, Certified 2021

Professional Memberships (selected)

- Diplomate, American Board of Dermatology
- Fellow, American Academy of Dermatology (FAAD)
- Fellow, American Society of Mohs Surgery (ASMS)
- Fellow, American Society for Dermatologic Surgery (ASDS)
- Member, American Academy of Cosmetic Surgery
- Member, American Society of Cosmetic Dermatology and Aesthetic Surgery
- Member, American Society for Laser Medicine and Surgery

CLINICAL EXPERIENCE

- 08/2008 - Present: Dermatologist / Mohs Surgeon, Simzar Dermatology Inc, Los Angeles, CA

EDUCATION AND TRAINING

- 2009 - 2010: Fellowship, Cosmetic and Procedural Dermatology (Dermatology and Laser Center); Mentor: Michelle Ehrlich, MD
- 2009: Mentorship, Blepharoplasty/Transconjunctival Blepharoplasty; Mentor: Henry Bayliss, MD
- 2008 - 2009: Dermatology Chief Resident, Harbor-UCLA Medical Center
- 2006 - 2009: Dermatology Residency, Harbor-UCLA Medical Center
- 2005 - 2006: Internal Medicine Residency, Olive View-UCLA Medical Center
- 2001 - 2005: Doctor of Medicine, UCLA School of Medicine (Alpha Omega Alpha)
- 1996 - 2001: B.S., Neuroscience, UCLA (Phi Beta Kappa; Summa Cum Laude)
- 1992 - 1996: Van Nuys Medical Magnet High School (Top 1%)

EXPERT WITNESS SERVICES

- Medical record review, written opinions, deposition, and trial testimony
- Standard of care analysis across medical, surgical, and cosmetic dermatology
- Differential diagnosis and clinical decision-making analysis (diagnosis, treatment selection, follow-up, and escalation of care)
- Causation and damages analysis related to scarring, disfigurement, functional impairment, wound complications, burns, dyspigmentation, and aesthetic outcomes
- Evaluation of consent processes, counseling, referral/triage decisions, and documentation quality in outpatient dermatology settings

PUBLICATIONS (SELECTED)

- Basile AL, Simzar S, Bentow J, Antelo F, Shitabata PK, Peng SK, Craft N. Disseminated Strongyloides stercoralis: hyperinfection during medical immunosuppression. JAAD. Feb 2010.
- Basile AL, Haghghi M, Simzar S, Craft N, Peng SK, Shitabata PK. Neutrophilic eccrine hidradenitis: expanding the clinical spectrum in non-chemotherapy patients. JAOCD. Sept 2008;12(1):41-45.
- Simzar S. Practical Reviews in Dermatology. Monthly peer-reviewed dermatology publication and audio CD with the latest dermatology research publications.
- Yoo S, Simzar S, Han K, Takahashi S, Cotliar R. Erythrokeratoderma variabilis successfully treated with topical tazarotene. Pediatr Dermatol. 2006;23(4):382-385.
- Simzar S, Rotunda AM, Craft N. Scrotal ulceration as a consequence of all-trans-retinoic acid for promyelocytic leukemia. J Drugs Dermatol. 2005;4(2):231-232.

RESEARCH (SELECTED)

- 2005: Effect of clobetasol on epidermal adhesion strength. Harbor-UCLA Division of Dermatology. Mentor: Michael Kolodney, MD, PhD.
- 2003 - 2004: Corticosteroids strengthen keratinocyte cell-cell adhesion. UCLA Division of Dermatology. Mentor: Michael Kolodney, MD, PhD.
- VisualDX, Dermatology Module. UCLA Division of Dermatology. Mentor: Noah Craft, MD, PhD.
- 2002: Keratinocytes expressing Rho family mutants. UCLA Division of Dermatology. Mentor: Michael Kolodney, MD, PhD.

CLINICAL RESEARCH TRIALS (SPONSOR NAMES REDACTED)

- 2025 X XXXXXXXX XXXXX XXXXXXXXXXXXXXXXXXXXX, Inc., CLIN-10200-459. Phase III, multicenter, double-blind, randomized, placebo-controlled study evaluating a single dose of IPN10200 for improvement of moderate to severe glabellar lines.
- 2025 X XXXXXXXX XXXXX XXXXX XXXXXXXX, Inc., NT-PPR-US001. Phase 3, randomized, double-blind, multicenter study evaluating NT 201 versus placebo for moderate to severe platysma prominence.
- 2024 X XXXXXXXX XXXXXXX, Inc., EVO-CLIN-202. Multi-center, double-blinded, randomized, non-inferiority IDE pivotal study evaluating Evolysse Lips for lip augmentation.
- 2024 X XXXXX XXXXXXX XXX XXXX, J-001-US. Multicenter, randomized, double-blind, placebo-controlled, single-dose Phase 2 study of JTM201 (botulinum toxin type A) for moderate/severe glabellar lines.
- 2023 X XXXXXXXX XXXXXXXX XXXXXXXXXXXXX, an XXXXXXX Company, M21-845. Study evaluating NOA HYDRATION compared to SKINVIVE by JUVEDERM for cheek skin smoothness/hydration.
- 2023 X XXXXXXXX XXXXXXXX XXXXXXXXXXXXX, an XXXXXXX Company, M21-842. Study evaluating NOA LIFT compared to JUVEDERM VOLLURE XC for correction of facial wrinkles/folds.
- 2023 X XXXXXXXX XXXXX XX, part of the XXXXXXXX Group, 43N3US2204. Randomized, evaluator-blinded study evaluating GP0116 for correction of dynamic facial wrinkles/folds (e.g., nasolabial folds).
- 2023 X XXXXXXXX XXXXXXXX, TEO-RHA 2203. Randomized, blinded evaluator, no-treatment control study of RHA 4 for correction of sagging jawline.
- 2023 X XXXXX XXXXXXX XX, part of the XXXXXXXX Group, 43N1US2102. Randomized, evaluator-blinded study evaluating GP0112 for cheek augmentation and midface volumization.
- 2022 X XXXXX XXXXX, M930041001. Prospective, randomized, evaluator-blinded study evaluating Belotero Intense Lidocaine for lip augmentation.
- 2022 X XXXXXXXX XXXXXXXX XXXXXXXXXXXXX, an XXXXXXX Company, M21-416. BOTOX (onabotulinumtoxinA) for reduction of masseter muscle prominence (Phase 3).

- 2022 X XXXX XXXXXXXX, TEO RHA 2004. Randomized, blinded evaluator study evaluating RHA 4 versus JUVEDERM VOLUMA XC for midface volume deficiency (pivotal).
- 2022 X XXXX XXXXXXXX XXXXXXXXXXXX, an XXXXXX Company, M21-323. Phase 3 open-label extension evaluating safety of botulinum toxin for platysma prominence.
- 2022 X XXXX XXXXXXXX XXXXXXXXXXXX, an XXXXXX Company, M21-509. Phase 3 open-label safety study of AGN-151586 for glabellar lines.
- 2022 X XXXX XXXX XXXXX XXXXXXXX, M930521003. Prospective, evaluator-blind study of diluted RADIESSE for decollete wrinkles.
- 2021 X XXXX XXXXXXX XXXXXXXXXXXXXXXXXX XXX, RZL-012-SMF-P2BUS-001. Double-blind Phase 2b study of RZL-012 for submental fat reduction.
- 2021 X XXXX XXXXXXXX XXXXXXXXXXXXXXX, an XXXXXX Company, M21-309. Phase 3 randomized, double-blind study evaluating botulinum toxin for platysma prominence.
- 2020 X XXXX XXXXXXXX XXXXXXXXXXXXXXX, 1920201. Phase 2 open-label study evaluating daxibotulinumtoxinA for combined upper facial lines.
- 2020 X XXXX XXXXX XX, a XXXXXXXX affiliate, 43QM1902. Multicenter, randomized, double-blind study evaluating QM1114-DP for lateral canthal lines and glabellar lines (READY-3).
- 2020 X XXXX XXXXXXXXXXXXXXX XXXX, CPH-201-201461. Double-blinded randomized controlled study comparing botulinum toxin type A products for glabellar lines (Phase 3).
- 2020 X XXXX XXXXXXXX, TEO RHA 1806. Controlled, randomized, double-blind study evaluating RHA 3 versus Restylane-L for lip augmentation (pivotal).
- 2020 X XXXX XXXXXXXX, TEO RHA 1902. Randomized, blinded evaluator, no-treatment control study of RHA 1 for infraorbital tissue volume deficiencies (pivotal).
- 2019 X XXXX XXXXXXXX, 1867-701-008. Randomized evaluator-blind study evaluating JUVEDERM VOLITE XC for cheek skin smoothness.
- 2019 X XXXX XXXXX XXXXXXXXXXXXXXX, NP-SH-009. Optimization study evaluating nano-pulse stimulation for sebaceous hyperplasia.
- 2019 X XXXX XXXXXXXXXXXXXXX XXXX, CPH-301-201200F. Randomized, split-face clinical investigation evaluating Princess FILLER Lidocaine for nasolabial folds.
- 2019 X XXXX XXXXXXXX XXXXX XXX, 2034-201-008. Phase 2b dose-ranging study of AGN-15186 for glabellar lines.
- 2018 X XXXX XXXX, M900391004. Study evaluating Radiesse (+) to improve jawline contour by adding volume.
- 2018 X XXXX XXXXXXXX XXXXXXXX, BBI-4000-CL-303. Multicenter, open-label Phase 3 long-term safety study of topical sofpironium bromide for axillary hyperhidrosis.
- 2018 X XXXX XXXXXXXX, 43USD1802. DREAM study evaluating subject satisfaction with abobotulinumtoxinA for glabellar lines.
- 2017 X XXXX XXXXXXXX, 1620303. Open-label safety study of daxibotulinumtoxinA for glabellar lines (SAKURA open-label).
- 2017 X XXXX XXXX, EN3835-205. Phase 2 open-label study of EN3835 for edematous fibrosclerotic panniculopathy.
- 2016 X XXXX XXXXXXXX, TEO-RHA-1501. Randomized, blinded, no-treatment control study of TEOSYAL RHA Redensity for perioral rhytids.
- 2016 X XXXX XXXXXXX XXXX, 1064.1100_FA. Clinical investigation of topical silver particle solution followed by 1064 nm laser for acne vulgaris.
- 2016 X XXXX XXXXXXXX, 1620301. Phase 3 randomized, double-blind study of daxibotulinumtoxinA for glabellar lines (SAKURA-1).

- 2015 X XXXX XXXXXXXX, RT001-CL038. Phase 3 randomized, double-blind study of RTT150 topical gel for lateral canthal lines.
- 2014 X XXXX XXXXXXXX, XXXXXXX CLIN-001. Phase III randomized double-blind trial of DWP-450 for glabellar lines.
- 2014 X XXXX XXXXXXXX, XXXXXXX-CLIN004. Phase II open-label trial evaluating safety of DWP-450 for glabellar lines.
- 2014 X XXXX XXXXXXXX, TEO-RHA-1302. Controlled, randomized, double-blind study comparing TEOSYAL RHA products versus Juvéderm Ultra XC for nasolabial folds.
- 2013 X XXXX XXXXXXXX, Volbella-004. Double-blind randomized controlled study of Juvéderm Volbella XC for lip and perioral enhancement.
- 2013 X XXXX XXXXXXXX, M518101-US04. Open-label long-term study evaluating investigational drug in plaque psoriasis.
- 2012 X XXXX XXXXXXXXXXXX, ML28296. Observational study of treatment patterns and outcomes in advanced basal cell carcinoma and basal cell nevus syndrome (RegiSONIC).
- 2009 X XXXXXXXX XXXXXXX XXXXXXXXXXXXXXXX, P10-023. Post-marketing observational registry assessing long-term safety of Humira in chronic plaque psoriasis.

HONORS AND AWARDS

- Super Doctors Rising Stars, Los Angeles Magazine (2013-present)
- American Society of Dermatologic Surgery Preceptorship Award (2008)
- Letters of Distinction, UCLA School of Medicine (Ambulatory Medicine; Pediatrics) (2004)
- Western Student Medical Research Forum Subspecialty Award (2003)
- UCLA Alumni Service Award for volunteer service at Santa Monica-UCLA Medical Center (2000)

POSTER PRESENTATIONS

- American College of Physicians Internal Medicine, All-California Scientific Meeting (2006)
- Senior Scholarship Day, UCLA School of Medicine (2005)
- Western Student Medical Research Forum, Carmel, CA (2003)

SERVICE AND TEACHING (SELECTED)

- Venice Free Family Clinic: Volunteer, dermatology clinic (2002 - 2009)
- UCLA School of Medicine: Embryology course lecturer (2002)
- Care-Extender Volunteer Program, Santa Monica-UCLA Medical Center: Co-founder/coordinator; supervised, scheduled, and trained 300+ volunteers (1999 - 2002)

LANGUAGES

- Fluent in Farsi; conversational Spanish